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Synthesis of a Novel Bicyclic Scaffold
Inspired by the Antifungal Natural Product
Sordarin
Yibiao Wu

Department of Chemistry, Marquette University, Milwaukee, WI

Chris Dockendorff

Department of Chemistry, Marquette University, Milwaukee, WI

Abstract
A simplified bicyclic scaffold inspired by the antifungal natural product sordarin was designed and
synthesized which maintains the carboxylic acid/aldehyde (or nitrile) pharmacophore. Docking studies
with the target for sordarin, the fungal protein eukaryotic elongation factor 2 (eEF2), suggested that the
novel scaffolds may bind productively. A densely functionalized chiral cyclopentadiene was constructed
in 8 steps and utilized in a Diels-Alder reaction with acrylonitrile. The resulting [2.2.1] cycloheptene was
transformed into a scaffold possessing vicinal carboxylic acid and nitrile groups, with orientations

predicted to provide high affinity for eEF2. The synthetic approach disclosed here sets the stage for a
renewed medicinal chemistry campaign against eEF2.

Graphical abstract
A simplified bicyclic scaffold inspired by the natural product sordarin was designed and synthesized
which will facilitate the preparation of novel antifungal agents.

Keywords Function-oriented synthesis; Antifungal agents; Sordarin; Diels-Alder reaction
An estimated 1.5 million people die each year from invasive fungal infections (IFIs) [1]. Clinical
options for the treatment of IFIs are extremely limited and generally only include a small number
of azole, echinocandin, and polyene (amphotericin B) antifungals. Of these treatments, only the azoles
are orally available, but their value has been diminished by the increasing prevalence of resistant
strains [2]. For these reasons, novel classes of antifungal drugs are urgently needed [3]. In the 1990s it was
discovered that derivatives of the natural product sordarin (1), known since the 1960s as an
antibacterial and antifungal agent [4], are highly active against pathogenic fungal species, particularly C.
albicans (Fig. 1, e.g. 3 to 5) [5], [6], [7]. A mode of action was deduced for sordarin that is unique for
antifungals, and appears to be related to that of the antibacterial fusidic acid[8], [9]. Sordarin halts protein
synthesis at fungal ribosomes by binding to eukaryotic Elongation Factor 2 (eEF2) and inhibiting the
interaction of eEF2 with ribosomal stalk proteins [10], [11], [12]. Importantly, sordarin derivatives are able to
selectively eradicate numerous fungal strains, including fluconazole-resistant C. albicans, without
significant toxicity to mammalian cells [13], are orally available, and have shown promising results in
animal models of invasive fungal infections [7], [14], [15], [16].

Figure 1. SAR of semisynthetic sordarin analogs and designed simplified bicyclic scaffold.

Despite significant efforts by the pharmaceutical industry in the 1990s and early 2000s to
develop semisynthetic sordarin analogs via ready modification of the glycosyl portion of the molecule,
no eEF2 inhibitors have advanced to clinical stages. The unmet potential of this class of molecules is
amplified by findings that some derivatives also show broad spectrum activity, including against
pathogenic Aspergillus species (5, Fig. 1) [7]. However, this potential is attenuated by the synthetic
challenge of modifying the complex sordarin core, which is prone to in vivo oxidation of
the cyclopentane ring to generate poorly active metabolites [17], [18]. Impressive total syntheses of
sordarin or its aglyconesordaricin have been reported by Kato [19], Mander [20], and Narasaka [21], but the
reported routes are lengthy and not amenable to convenient modifications of the sordarin core.
Our interest in function-oriented synthesis [22] as a strategy for simplifying and modifying natural
products [23] led us to re-examine the complex diterpene core of sordarin, with the goal of generating
novel scaffolds that could be more easily modified to improve properties such as metabolic stability and
activity against resistant strains. An unsuccessful attempt at identifying a simplified sordarin scaffold
with potent antifungal activity was reported by Cuevas in 1998, involving a monocyclic cyclopentane[17],
but otherwise we are not aware of the de novo synthesis of sordarin-inspired scaffolds for antifungal
applications. Novel scaffolds and synthetic approaches to this class of inhibitors could reignite the
dormant interest in eEF2 as a target for potent and safe antifungal agents.
More recently, our interest in novel scaffolds is supported by the x-ray crystal structures of
sordarin or related compounds with eEF2 that were reported subsequent to the majority of
semisynthetic medicinal chemistry efforts [9], [24], [25]; these could enable the prioritization of novel
compound designs with routine docking algorithms. Published patents and structure-activity
relationship (SAR) studies, and inspection of the sordarin–eEF2 x-ray structure reported by Andersen [24],
highlight the necessity of a carboxylic acid at C1 and an aldehydeor nitrile [5] at C2 of the bicyclic core of
sordarin (Fig. 2). A carboxylic acid at the bridgehead position of the scaffold forms hydrogen bonds with
a backbone amide (Glu524) of eEF2, as well as two bridging water molecules (Fig. 2, left). The acid
moiety is essential for activity, and no alternative functional groups have been reported to be effective.
The aldehyde of sordarin acts as a hydrogen bond acceptor for the backbone amide of Ala562; a nitrile
was reported to be an effective replacement of this aldehyde moiety, and in some cases was more
potent [5]. Interestingly, the glycosyl moiety is not critical for activity against specific strains, and highly
potent analogs have been reported possessing aliphatic alkyl chains [5].

Figure 2. X-ray structure of sordarin with eEF2 (left); docked structure of designed analog 2a (right).
With this and other SAR data in mind, we designed novel scaffolds that maintain
the pharmacophore of sordarin, but with removal of the fused cyclopentane ring, and replacement with

alternative metabolically stable groups (2, Fig. 1). We hypothesized that scaffolds with decreased
complexity such as 2could also facilitate SAR studies and the subsequent improvement of
physico/physiochemical properties that are not feasible with the natural scaffold. A docking study was
performed with compounds of type 2 and the sordarin–eEF2 x-ray structure (PDB 1N0U[24]) using
FITTED® by Molecular Forecaster [26]. Our simplified sordarin analogs generally yielded similar docking
poses to sordarin and comparable docking scores to compounds with simple alkyl glycosyl replacements
such as 3that have been reported to be potent antifungal agents against S. cerevisiae[5]. A representative
docking pose is given in Fig. 2(right), in comparison to the x-ray structure in Fig. 2 (left) of sordarin with
eEF2, which suggests that nitriles such as 2a will indeed be able to effectively replace
the aldehyde moiety of sordarin as an H-bond acceptor for the backbone amide of Ala 562.
A retrosynthesis of compounds of type 2 is depicted in Fig. 3. The Diels-Alder cycloaddition could
permit the late stage introduction of a variety of substituents at C-2. We prioritized nitrile-containing
compounds over aldehydes for their better stability and tolerance of a range of reaction conditions. For
ease of synthesis, we also prioritized analogs alkylated at C-5 instead of C-6, especially since the x-ray
structure of eEF2 suggests that various substituents could be tolerated in both
positions. Cyclopentadienes of type 6 were selected as key synthetic targets, with the silylether
substituent able to polarize the diene to provide the desired regioselectivity with the nitrile and latent
carboxylic acid moieties on adjacent carbons, as well as increasing its reactivity. A related intermolecular
Diels-Alder reaction was reported by Ciufolini [27]. One important disadvantage to substituted
cyclopentadienes is that they are prone to 1,5-hydride or alkyl shifts [28], but we were inspired by the
work of Gleason and coworkers disclosing that the silylether could greatly increase the stability of
cyclopentadienes to undesired hydride shifts (isomerization) [29]. Cyclopentadienes of type 6 could be
generated by enolization of an enone; enones of type 7 could be prepared via
a carbonylation of triflate 8, followed by an allylic oxidation reaction. Aldol
reaction between cyclopentanone and formaldehyde, with a subsequent generation of
the kinetic enolate and trapping with an appropriate electrophile, would generate enol triflate 8.

Figure 3. Retrosynthesis of simplified sordarin analogs.
The synthesis of the desired cyclopentadienes proceeded broadly according to plan, with
racemic materials generated in our first-generation synthesis disclosed here (Scheme 1). An excess
of cyclopentanone was reacted with formaldehyde in an aldol reaction [30], followed by distillation and

protection of the alcohol with TBDPSCl to generate large quantities of silylether 9, after recrystallization.
After screening several bases and electrophiles, the kinetic enol triflate 10 was obtained in quantitative
yield using NaHMDS and PhNTf2 at –40 °C. Palladium-catalyzed carbonylation and trapping
with methanolproceeded smoothly to yield enoate 11. Allylic oxidation using Corey’s reported protocol
(t-BuOOH, cat. Pd(OH)2/C) yielded enone 12[31]. Reduction of both the ketone and ester moieties with
DIBAL-H generated a diol intermediate as an inconsequential mixture of diastereomers, which was
acetylated selectively at the primary alcohol to give 13, then the secondary alcohol was oxidized with
PCC to yield the enone 14.

Scheme 1. Synthesis of cyclopentenone 14.
Enone 14 was treated with TBSOTf and base to generate cyclopentadiene 15, which was
subjected to a variety of Diels-Alder reactions with different aldehyde, ester, and nitrile-containing
dienophiles (Scheme 2). The most useful product was obtained from reaction with excess acrylonitrile;
even though a 1:1 mixture of endo/exo diastereomers was obtained, these were separable
by chromatography at a later stage. Diels-Alder reactions with carboxyl-substituted cyclopentadienes
(instead of hydroxymethyl-substituted systems such as 15), were unsuccessful, likely due to poor
matching of HOMO/LUMO levels.

Scheme 2. Synthesis of first-generation antifungal scaffold: bicyclic nitrile acid 23.
The racemic mixture of cycloadducts 16 underwent selective removal of the silylenol ether using
BF3 etherate [32]. The remaining acetate protecting group proved to be problematic for several
transformations, so it was removed under basic conditions, and
the endo/exo diastereomeric alcohols were separated by flash chromatography; the isolated yield is not
reflective of mixed fractions that were omitted. The desired endoproduct 17a and exo
diastereomer 17b were isolated and assigned via COSY and NOESY NMR, inspection of the 1H
NMR coupling constants, and comparison to literature coupling constants. Protons b and c (Scheme 2,
bottom) of the exo isomer 17b were differentiated by the negligible coupling of Hb with the bridgehead
Hd, due to a dihedral angle approaching 90° [33]. 3Jab(9.2 Hz) is consistent with the cis coupling reported
by Williamson for a nitrile-substituted bicyclo[2.2.1]heptene (9.3 Hz) [34], therefore our data are
consistent with Ha of 17b residing on the endo face of the bicycle (see Supporting Information for
spectra).
Initial efforts at protection of 17 with PMB or Bn were unsuccessful, so a THP protecting
group was utilized to cleanly give 18. Several functional group transformations of the C-5 ketone are
presently being explored, but to maintain lipophilicity on the eastern face of the bicycle we elected to
methenylate the ketone with a Wittig reaction. Elevated temperatures were required (90 °C), but
the alkene 19 was cleanly obtained without epimerization of the α-nitrile carbon. Removal of the TBDPS
protecting group with TBAF and alkylation of the resulting alcohol with n-pentyl iodide generated
the ether 21, containing a simple alkyl chain analogous to those on sordarin analogs reported to be
highly potent against S. cerevisiae[5]. Analogs with extended alkyl chains are not expected to be
metabolically stable (due to their likely accessibility to the active site of cytochromes P450), but for ease
of synthesis we elected to build such an analog first to validate the scaffold synthesis prior to attaching
more complex glycosyl groups presumably required for high potency against species such as C. albicans.
The THP group of 21 was removed under acidic conditions, then subjected to a Jones oxidation to
generate the desired carboxylic acid 23, which represents our first simplified sordarin analog.

Though it was inactive against several strains of C. albicans at concentrations up to 8 μg/mL
using the CLSI M27-A3 broth microdilution method (RPMI + MOPS, pH 7.0 as the liquid medium), the
preparation of 23 validates our intermolecular Diels-Alder strategy towards the preparation of
functionalized bicyclic scaffolds with the requisite positioning of carboxylic acid and aldehyde/nitrile
moieties for inhibition of fungal eEF2. Our present efforts are directed towards the addition of alkyl and
aryl substituents at C-2, the incorporation of validated glycosylgroups, and the development of
an asymmetric synthesis of the desired bicyclic scaffolds. Our novel synthetic strategy facilitates the
exploration of unaddressed structure-activity relationships of sordarin-type eEF2 inhibitors, and may
lead to the identification of antifungal agents with improved properties.
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